Melasma
Conditions
Interventions
Trial group:According to the random table, use the test product on one half of the face
Control group:According to the random table, use the control product on the other half of the face
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Female
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Female, aged 20–50 years; 2. Clinically diagnosed with melasma, with a half-face MASI score >1.25; 3. Skin type III or IV; 4. No other depigmenting treatments received in the past 3 months; 5. Willing to undergo IPL treatment; 6. Willing and able to complete the entire study and follow-up schedule; 7. Informed about the study and has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or planning to become pregnant during the study period, or failure to take effective contraceptive measures; 2. Suffering from photosensitive diseases such as lupus erythematosus, photodermatitis, porphyria, etc.; 3. Taking photosensitizing drugs or ingredients, such as retinoic acid, tetracycline antibiotics, sulfonamides, etc.; 4. Obvious wounds, abrasions, or other skin damage present at or near the test site; 5. Patients with severe skin or systemic diseases, such as skin cancer, severe heart disease, or immunodeficiency; 6. Received other cosmetic medical treatments within the past month; 7. Deemed unsuitable for participation in the trial based on clinical evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma MASI score;Melasma Area Assessment;Skin melanin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Facial Pigmentation Analysis;Moisture content of skin stratum corneum;Loss rate of epidermal water diversion;Safety assessment (including any adverse reactions, such as erythema, edema, papules, stinging, etc.); | — |
Countries
China
Contacts
Public ContactWang Xi
West China Hospital, Sichuan University
Outcome results
None listed